MONDAY, OCTOBER 23, 2017

VBI provides update on hepatitis C vaccine research at conference

VBI Vaccines recently presented the latest data about its eVLP platform being used in creating a new hepatitis C vaccine candidate at the World Vaccine Congress Asia, held Wednesday and Thursday at the Suntec Singapore Convention & Exhibition Centre in Singapore. Read More »

Visterra collaborates with A*STAR to make monoclonal antibody for dengue

Visterra Inc., a clinical-stage biotechnology company with a unique technology platform to discover disease targets and create novel treatments for infectious diseases, and the Agency for Science, Technology and Research’s (A*STAR) Drug Discovery and Development (D3) unit, recently partnered to create VIS513 -- Visterra’s treatment that uses broadly neutralizing antibodies to fight dengue fever. Read More »

Microfluidic cell-squeezing tool shows promise for cell-based vaccines

Massachusetts Institute of Technology researchers recently demonstrated a microfluidic cell-squeezing device that introduces antigens to the body’s immune system’s B cells, a tool that may open a new approach to creating and implementing cell-based, antigen-presenting vaccines. Read More »

VBI Vaccines to present at Modern Vaccines Adjuvants & Delivery Systems Conference

VBI Vaccines will make a presentation titled “Optimization of the Process for Making Clinical Supplies of an Enveloped Virus-like Particle for Cytomegalovirus (CMV)” Monday at the Modern Vaccines Adjuvants & Delivery Systems Conference. Read More »

Agenus testing shows promising results for herpes vaccine

Agenus Inc. -- an immune-oncology company that creates heat shock protein peptide-based vaccines, checkpoint modulators (CPMs), and adjuvants -- recently announced promising results from its HerpV synthetic vaccine Phase 2 trial. Read More »

First measles case of 2015 confirmed in Massachusetts

A recent announcement from the Hinton State Laboratory has confirmed the first measles case for 2015 in the state of Massachusetts. Read More »

Merck re-commits to innovative infectious disease medicines

At the 25th European Congress of Clinical Microbiology and Infectious Diseases in Copenhagen, Denmark, Merck will re-commit itself to creating innovative medicines to treat infectious diseases as health professionals around the world battle infectious illnesses from various pathogens. Read More »

Study shows anti-virals battle HIV via mutational meltdown

Researchers from the Massachusetts Institute of Technology (MIT) and the University of Chicago recently created a spectroscopy method that illustrates how anti-HIV drugs provoke lethal mutations within HIV’s genetic material, a discovery that sheds light on a process that has been poorly understood in the past and may improve attempts to create novel anti-viral treatments. Read More »

Spring Bank Pharmaceuticals to present HBV and HCV treatment candidate

Spring Bank Pharmaceuticals Inc., a clinical-stage biopharmaceutical company that creates novel therapeutics to treat viral infections, has recently announced that a company representative will present its lead drug candidate, SB 9200, for treating infections of hepatitis B virus (HBV) and hepatitis C virus (HCV). Read More »

VBI Vaccines and Sanofi Pasteur partner to increase vaccine stability

According to a recent announcement from VBI Vaccines Inc., VBI has partnered with Sanofi Pasteur to improve the stability of vaccines. Read More »

Alere supports Obama’s National Action Plan to combat Antibiotic-Resistant Bacteria

Alere Inc., a rapid diagnostics company, has formally announced its support of President Barack Obama's National Action Plan to combat Antibiotic-Resistant Bacteria. Read More »

Data suggest low vaccination rates, measles outbreak related

Researchers at Boston Children’s Hospital recently published a report from epidemiological data that suggest there is a correlation between low vaccination rates and the measles outbreak of 2015. The researchers said the general population has received far fewer vaccines than what is needed to stop a measles outbreak. Read More »

New UK study unveils stronger vaccine to fight HPV

Scientists have developed a new HPV vaccine that potentially protects against nine types of the virus. Read More »

Vaxxas set to develop Nanopatch 'needle-free' vaccines

Vaxxas said this week that it has raised $20 million for a series of clinical programs toward development of a line of vaccine products using the company's Nanopatch platform, which utilizes painless microneedles. Read More »

Vaxxas secures $20 million for Nanopatch vaccine programs

Biotechnology company Vaxxas said on Monday that it has obtained $20 million in equity funding from new and existing investors. Read More »